Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Segment Information (Tables)

v2.4.1.9
Note 4 - Segment Information (Tables)
 6 Months Ended
Dec. 31, 2014
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
Six Months Ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2014
 
 
2013
 
 
2014
 
 
2013
 
Net sales:
                                
Biotechnology
   $ 77,951     $ 70,557     $ 159,419     $ 143,747  
Clinical Controls
     13,698       13,460       27,793       25,938  
Protein Platforms
     20,299       0       33,213       0  
Consolidated net sales
   $ 111,948     $ 84,017     $ 220,425     $ 169,685  
                                 
Segment operating income
                                
Biotechnology
  $ 39,210     $ 38,135     $ 81,230     $ 79,123  
Clinical Controls
    3,818       3,686       8,353       7,705  
Protein Platforms
    3,567       0       6,171       0  
Subtotal reportable segments
    46,595       41,821       95,754       86,828  
                                 
Cost recognized on sale of acquired inventory
     (1,188
)
     (1,404
)
     (4,355
)
     (3,135
)
Amortization of acquisition related intangible assets
     (6,858
)
     (2,587
)
     (12,586
)
     (4,775
)
Corporate selling, general and administrative expenses
     (2,768
)
     (2,086
)
     (5,446
)
     (3,251
)
Acquisition related expenses
     (1,201
)
     (0
)
     (3,571
)
     (532
)
Consolidated operating income
   $ 34,580     $ 35,744     $ 69,796     $ 75,135